Home › Non-Small Cell Lung Cancer › Colorado › Grand Junction
Non-Small Cell Lung Cancer clinical trials in Grand Junction, CO
8 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Grand Junction (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RecruitingPhase 3
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- Intermountain Health, Grand Junction
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Local Institution - 0500, Grand Junction
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Grand Junction
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Grand Junction
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
RecruitingPhase 3
- Intermountain Health St. Mary's Regional Hospital ( Site 0116), Grand Junction
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Grand Junction
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.